title: Results of phase I/II trials with recombinant human interleukin-3.
authors.affiliation: Department of Hematology, University of Frankfurt, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: O G
authors.initials: OG
authors.lastname: Ottmann
authors.forename: G
authors.initials: G
authors.lastname: Seipelt
authors.forename: M
authors.initials: M
authors.lastname: Eder
authors.forename: G
authors.initials: G
authors.lastname: Geissler
authors.forename: R
authors.initials: R
authors.lastname: Merget
authors.forename: A
authors.initials: A
authors.lastname: Maurer
authors.forename: S
authors.initials: S
authors.lastname: Falk
authors.forename: A
authors.initials: A
authors.lastname: Lindemann
authors.forename: F
authors.initials: F
authors.lastname: Herrmann
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy; D000818:Animals; D001855:Bone Marrow Diseases / Q000628:therapy; D004353:Drug Evaluation, Preclinical; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007377:Interleukin-3 / Q000009:adverse effects / Q000627:therapeutic use*; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009369:Neoplasms / Q000628:therapy; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D007377:Interleukin-3; D011994:Recombinant Proteins